Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

By Dr. Matthew Watson

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.

Continued here:
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The... - October 13th, 2024
Better Choice Company to Expand into Veterinary Medicine in 2025 Following the Acquisition of SRx Health - October 13th, 2024
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting - October 13th, 2024
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - October 13th, 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - October 13th, 2024
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 - October 13th, 2024
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024... - October 13th, 2024
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat - October 13th, 2024
23andMe Announces 1-for-20 Reverse Stock Split - October 13th, 2024
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit - October 13th, 2024
Firefly Neuroscience to Participate in Upcoming October Investor Conferences - October 13th, 2024
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - October 13th, 2024
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing - October 13th, 2024
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - October 13th, 2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID - October 13th, 2024
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 - October 13th, 2024
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - October 13th, 2024
Quest PharmaTech Announces Results from AGM - October 13th, 2024
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the... - October 13th, 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union - September 23rd, 2024
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed - September 23rd, 2024
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - September 23rd, 2024
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with... - September 23rd, 2024
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union - September 23rd, 2024
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - September 23rd, 2024
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - September 23rd, 2024
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs - September 23rd, 2024
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - September 23rd, 2024
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 23rd, 2024
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024 - September 23rd, 2024
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly... - September 23rd, 2024
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release... - September 23rd, 2024
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous... - September 23rd, 2024
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - September 23rd, 2024
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s... - September 23rd, 2024
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia - September 23rd, 2024
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA... - September 23rd, 2024
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement - September 23rd, 2024
Synergia Medical Successfully Implants First Patients With NAO.VNS™ - September 23rd, 2024
Tr1X to Participate at Upcoming Healthcare Investment Conferences - September 14th, 2024
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 - September 14th, 2024
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - September 14th, 2024
CorMedix Inc. to Present at the Cantor Global Healthcare Conference - September 14th, 2024
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress - September 14th, 2024
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - September 14th, 2024
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial... - September 14th, 2024
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - September 14th, 2024
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th - September 14th, 2024
Virbac 2024 half-year results - September 14th, 2024
Virbac: Information on the departure of Sébastien Huron - September 14th, 2024
Virbac : the board of directors announces a capital reduction through cancellation of treasury shares - September 14th, 2024
Virbac : Public release of the Half-Year Financial Report at 30 June 2024. - September 14th, 2024
Virbac : Half-yearly financial report 2024 - September 14th, 2024
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - September 14th, 2024
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq - September 14th, 2024
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - September 14th, 2024
Company Statement on FDA Advisory Committee Meeting - September 14th, 2024
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of... - September 14th, 2024
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - September 14th, 2024
Total number of shares and voting rights in Zealand Pharma on August 30, 2024 - September 3rd, 2024
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with... - September 3rd, 2024
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update - September 3rd, 2024
Receipt of Nasdaq Delisting Determination - Plans to Appeal - September 3rd, 2024
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop... - September 3rd, 2024
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates - September 3rd, 2024
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC... - September 3rd, 2024
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - September 3rd, 2024
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 - September 3rd, 2024
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in... - September 3rd, 2024
PCI Biotech: Employee share option scheme - September 3rd, 2024
Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK - September 3rd, 2024
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today - September 3rd, 2024
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 3rd, 2024
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and... - September 3rd, 2024
Amended terms of Idorsia’s 2024 convertible bonds become effective - September 3rd, 2024
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine... - September 3rd, 2024
CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive Committee member to develop CARBIOS’ presence with brands worldwide - September 3rd, 2024
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate - September 3rd, 2024
QIAGEN N.V. launches non-US offering of net share settled convertible bonds - September 3rd, 2024
Structure Therapeutics Announces Participation in Upcoming Investor Conferences - August 27th, 2024

Global News Feed commento

Comments Off | data

October 13th, 2024

About... Dr. Matthew Watson

This author published 5812 posts in this site.

Comments are closed.

Previous post - Next post

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites